Syncona Limited (SYNC)
Category Alternative Other
This investment trust can be held in an Investment ISA, SIPP and Investment Account
Some Investment Trusts include direct costs as part of their Ongoing charge, such as the annual management charge. For those that show Ongoing charges as 0% or a dash please review the investment literature for details on the charges that will apply. The Financial Conduct Authority will review this in 2025.
If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice.
If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice.
Sell
88.30p
Buy
89.10p
-1.00p (-1.11%)
Discount/Premium
-49.83%
Estimated NAV
179.40p
Prices updated at 07 May 2025, 16:39 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Investment objective
The Company’s investment objective is to achieve superior long-term capital appreciation from its investments. The Company invests in life science businesses and single or multi-asset projects. The Company targets an annualised return per share across its investment portfolio of 15 per cent per annum over the long term.
Important notice: This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements for retail clients.
Important documents: Please ensure that you have read the Key Information Document/Technical Guide
, Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.
- Key stats
- Price
- Performance
- Charges & documents
- Shares & trades
- Dividends
- Portfolio
- News & dates
- Trust info
- Director info
Company name
Syncona Investment Management Limited
Legal structure
Closed Ended Investment Company
Domicile
Guernsey
Fiscal year end
31 Mar 2026
Launch date
26 Oct 2012
Fund manager
Chris Hollowood
Manager start date
26 Oct 2012
Fund manager biography
Chris is the Chief Executive Officer of Syncona Investment Management Ltd. He has been instrumental in the foundation and development of Syncona's gene therapy strategy, where it has founded companies focused on the eye, the liver, the kidney, and central nervous system. He is Chairman of Spur and Purespring, and is a Board member of Beacon and Yellowstone. He was also previously Chairman of retinal gene therapies Nightstar, which was sold to Biogen in 2019 for $877 million, and Gyroscope, which was sold to Novartis for $800 million in 2022. Previously, Chris was a partner of Apposite Capital LLP, a venture and growth capital healthcare investment company. Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry. Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from the University of Cambridge.
Head office
2nd Floor, 8 Bloomsbury Street,
London
United Kingdom
WC1B 3SR
